Roche's check­point play­er Tecen­triq flops in an­oth­er blad­der can­cer sub­set

Just weeks af­ter Mer­ck’s star check­point in­hibitor Keytru­da se­cured FDA ap­proval for a sub­set of blad­der can­cer pa­tients, Swiss com­peti­tor Roche’s Tecen­triq has failed in a piv­otal blad­der can­cer study.

The 809-pa­tient tri­al — IMvig­or010 — test­ed the PD-L1 drug in pa­tients with mus­cle-in­va­sive urothe­lial can­cer (MI­UC) who had un­der­gone surgery, and were at high risk for re­cur­rence.

The ther­a­py failed to meet the main goal of dis­ease-free sur­vival, Roche said, with­out dis­clos­ing de­tails.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.